Image

Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis

Recruiting
18 - 74 years of age
Both
Phase N/A

Powered by AI

Overview

The purpose of this study is to cast light on the highly complex etiology and cellular landscape of hip osteoarthritis by utilising single-cell and spatial transcriptomics.

Description

The specific objectives of this project are:

  1. Using the latest single-cell RNA sequencing (scRNAseq) techniques the investigators aim to A) characterize what kind of cell populations are found in different synovial tissues and blood derived samples of OA patients, B) determine how the cell composition differs between arthritic and corresponding non-arthritic tissues, C) map the transcriptional and regulatory landscape of the cells mentioned in A and B, D) determine what are the key molecular pathways activated in OA.
  2. To determine if some of the blood-derived immune cell populations could be used as biomarkers for OA.
  3. To map the whole transcriptome of OA and non-arthritic control tissue while keeping the morphological context with spatial transcriptomics technologies.
  4. Further differentiation and identification of OA endotypes utilizing the single-cell and spatial data.

The project includes a Rheumatoid sub-study where the main objective is to compare arthritic tissue and peripheral blood constituents between OA and rheumatoid arthritis patients to explore the differences in the disease mechanisms.

Eligibility

Inclusion Criteria for the main (OA) study:

        Cases: Adult patients with osteoarthritis in the hip joint and who are going through an
        elective total hip arthroplasty.
        Controls: Non-arthritis adult patients who are going through a trauma-based emergency total
        hip arthroplasty.
        ----
        Inclusion Criteria for the Rheumatoid sub-study:
        Adult patients with rheumatoid arthritis in the hip joint and who are going through an
        elective total hip arthroplasty.
        ----
        Exclusion Criteria:
          -  The body mass index must be below 35
          -  Age < 18 or > 74
          -  The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic
             syndrome.
        For the Rheumatoid sub-study, the exclusion criteria are the same as above except for the
        RA.

Study details

Osteoarthritis, Hip, Rheumatoid Arthritis

NCT05278520

University of Turku

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.